C2N Diagnostics Expands Portfolio of Blood Tests for Clinical Researchers Studying Alzheimer's Disease and Related Dementias
ST. LOUIS, July 15, 2025--(BUSINESS WIRE)--C2N Diagnostics, LLC, a pioneer in advanced diagnostic testing for brain health, announces the launch of two new highly anticipated plasma assays for Research Use Only: C2N eMTBR-tau243 and C2N %p-tau MAA.
C2N eMTBR-tau243 (endogenous Microtubule Binding Region) is a unique blood test that selectively detects a specific region of tau; this fragment has been shown to closely track insoluble tau aggregates within neurofibrillary tangles in Alzheimer's disease. C2N cites research that says this may provide the potential to improve the diagnostic evaluation of Alzheimer's pathology in clinical trials, supporting essential disease staging, predicting disease progression and response to treatment, and monitoring treatment efficacy.
This new plasma assay builds on the existing C2N eMTBR-tau243 test in cerebrospinal fluid launched by C2N nearly two years ago and is available for Research Use Only. C2N obtained the exclusive rights for these technologies from the Bateman Lab at WashU Medicine. With funding from the GHR Foundation, the C2N team optimized and industrialized these assays using rigorous analytical methods to bring them to their current state.
The company aims to integrate the new plasma C2N eMTBR-tau243 assay into clinical routine in the future.
C2N Increases Diagnostic Power With C2N %p-tau MAA
C2N is also launching a novel p-tau multi-analyte assay (MAA). This assay uses high-resolution mass spectrometry (LC-MS/MS) to precisely quantitate six analytes related to phosphorylated and nonphosphorylated forms of tau (%p-tau181, %p-tau205 and %p-tau217). The C2N %p-tau MAA measures multiple phosphorylated tau forms from a single sample and, therefore, enables greater efficiencies. This test is likewise available for Research Use Only.
C2N's LC-MS/MS methodologies enable a ratio of phosphorylated tau divided by non-phosphorylated tau (%p-tau) that previously has been shown to mitigate for confounding factors such as age and medical comorbidities like kidney disease. The Journal of the American Medical Association (JAMA) published a large clinical study that found C2N's PrecivityAD2™ test accuracy was not impacted in the primary care arm of the study despite having patients of older age and with higher prevalence of comorbidities.
The company believes the C2N %p-tau MAA and C2N eMTBR-tau243 assays will play a key role in biopharma clinical trials, enabling better assessment of Alzheimer's disease pathology and supporting a precision medicine approach to novel treatment strategies. The assays will cover both early-stage and late-stage tau pathology identification, providing a robust marker for disease identification, staging, and stratification.
"Our introduction of the C2N eMTBR-tau243 blood test and the C2N %p-tau MAA demonstrates C2N's commitment to clinically-relevant innovations and advancing brain health diagnostics, first as Research Use Only tools and then in the form of clinical diagnostic tests," says C2N CEO and President Dr. Joel Braunstein. "Patients and families worried about Alzheimer's disease are pressing on the entire healthcare sector for a clearer picture of Alzheimer's disease pathology. We are responding, first for researchers and then for the broader global healthcare provider community."
The Precivity™ line of blood tests currently available clinically to aid healthcare providers in the detection of amyloid plaques in the brain, a pathological hallmark of Alzheimer's disease, and inform medical management and treatment decisions are: PrecivityAD®, PrecivityAD2™, and Precivity-AopE™.
About C2N Diagnostics, LLC
C2N is a specialty diagnostics company with a vision to bring Clarity Through Innovation®. C2N strives to provide exceptional clinical laboratory services and advanced diagnostic solutions in the field of brain health. C2N's high-resolution mass spectrometry-based biomarker services and products are used for: clinical decision-making to improve patient care, including diagnosis and treatment monitoring; maximizing the quality and efficiency of clinical trials that test novel treatments for neurodegeneration; and providing innovative tools to help healthcare researchers better understand novel mechanisms of disease, identify new treatment targets, and conduct important epidemiologic studies to improve global public health. C2N assays have been used in over 150 Alzheimer's disease and other research studies throughout the U.S. and the world. This includes landmark treatment and prevention trials involving disease-modifying therapies (DMTs) that are changing the trajectory of Alzheimer's disease. C2N has ongoing collaborations with multi-national pharmaceutical and biotech companies, leading academic institutions, National Institute on Aging, Alzheimer's Association, and other non-profits and consortiums in addition to research and distribution partnerships with leading labs around the world including Grupo Fleury, Healius, Mediford, Mayo Clinic Laboratories, and Unilabs. Over 50,000 Precivity™-related biomarker measures have been reported through peer-reviewed publications, with many more manuscripts currently under review.
The company acknowledges generous support from National Institute on Aging, GHR Foundation, Alzheimer's Drug Discovery Foundation, BrightFocus Foundation, and Alzheimer's Association. For more information visit www.c2n.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250715238954/en/
Contacts
COMPANY CONTACT:Joni Hendersoninfo@C2N.com
MEDIA CONTACT:Adam ShapiroAdam.Shapiro@ASPR.bz 202-427-3603
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
4 hours ago
- Business Wire
Prima Mente Launches Pleiades, a Large-Scale Human Whole-Epigenome Foundation Model with Clinical Applications for Alzheimer's Disease
LONDON & SAN FRANCISCO--(BUSINESS WIRE)-- Prima Mente today announced the launch of Pleiades, a family of large-scale foundation models created to understand the epigenomic and molecular landscape of human disease. Pleiades represents generative transformers (90M, 600M, and 7B parameters) trained on 1.9 trillion tokens at single-nucleotide resolution. The work is introduced in a newly released preprint, authored in collaboration with researchers from University of Oxford, Hebrew University of Jerusalem, and University of Gothenburg. Trained on a methylation atlas of human cell types as well as cell-free DNA (cfDNA), Pleiades represents a new era in Alzheimer's research and translational medicine – offering the ability to detect disease-relevant signals from blood with unprecedented resolution across cellular subtypes, identify molecular profiles for experimental design, and reveal targets for early intervention. 'We believe epigenetics and cfDNA offer one of the most powerful, underutilized entry points into understanding the brain,' said Ravi Solanki, CEO of Prima Mente. 'They give us a non-invasive lens into cellular activity and dysfunction – particularly in neurodegeneration – at a resolution that was unimaginable just a few years ago. With Pleiades, we're building the AI infrastructure to translate that signal into meaningful discovery, diagnosis, and eventually, intervention.' In contrast to traditional models, Pleiades uses a large-scale transformer-based architecture to learn directly from raw sequencing data. It predicts the cell type of origin of cfDNA fragments, uncovers tissue and disease-specific methylation patterns, and generates synthetic cfDNA to power in silico experimentation. Critically, the team demonstrated that model performance scales reliably with data and compute, extending AI's scaling laws seen in large language and vision models to biology and laying the foundation for future multiomic modeling. The model has so far been applied to a variety of biological tasks, including tissue classification, disease detection, and fragment reconstruction, allowing it to generalize across tissues and diseases while learning shared representations of molecular function. In early Alzheimer's work, Pleiades has shown the ability to detect neuron- and microglia-, and T cell-derived cfDNA signatures that signal neurodegeneration before clinical symptoms appear. 'Pleiades represents an important step forward in how we study Alzheimer's disease using blood-based biomarkers,' said Professor Henrik Zetterberg, a leading researcher in neurodegeneration at the University of Gothenburg. 'Understanding the cell type origin and regulatory disruption at this level could enable earlier, more accurate diagnosis and reveal new biological pathways for intervention. I was thrilled to see the performance of the approach alongside the protein-based biomarkers—so much exciting research can be done and the technology really opens for personalized medicine approaches finding neurodegenerative disease subtypes with varying disease drivers.' Prima Mente has partnered with NVIDIA to scale training across DGX infrastructure, ensuring high-performance compute can be directed toward decoding the biology of complex disease. Additionally, to train and test Pleiades, Prima Mente worked with Nebius, Siam AI, and Eternis Labs for distributed compute infrastructure. The teams will continue to collaborate together on data collection and future training initiatives. Pleiades caps a period of strong momentum for Prima Mente. Alongside the model's release, the company built a wet lab for high-throughput multiomic data generation and has begun modeling disease progression across regulatory, transcriptomic, and proteomic layers. The company is launching a 1,000-patient Alzheimer's study next month and is actively building partnerships across AI, academia, and life sciences to translate these models into tools for discovery, diagnosis, and ultimately, intervention. About Prima Mente Prima Mente is based in San Francisco and London. Its mission is to build intelligent infrastructure to deeply understand the brain, protect it from neurological disease, and enhance it in health.
New York Post
4 hours ago
- New York Post
Getting more of this metal in your diet is good for your brain: study
Afraid of getting rusty? New research suggests increasing your dietary intake of a certain metal could give your brain a serious boost and might even help fend off cognitive decline as you age. But beware — too much can turn toxic. Luckily, Hebei Medical University think they've found the sweet spot. Advertisement 4 Cognitive function is one of the most critical aspects of healthy aging. Getty Images/iStockphoto In the study, researchers analyzed diet and health data collected from 2,420 Americans ages 60 and older over a four year period. They found those who consumed more copper in their daily diet scored significantly higher on cognitive tests than those with lower intake. The results held steady even after the team accounting for factors like age, sex, alcohol use and heart disease. The benefits appeared to be even greater for participants who'd previously suffered a stroke. Advertisement 'Dietary copper is crucial for brain health,' declared Professor Weiai Jia, the lead researcher of the study. Copper is a naturally occurring element and an essential nutrient the body needs for several functions. In their analysis, the scientists speculated that its brain benefits may come from copper's role in regulating neurotransmitters linked to learning, memory and alertness. Advertisement 4 Copper plays a critical role in brain functions crucial to memory and learning. Teeradej – Past research also shows copper helps generate energy in brain cells, protects them from damage and boosts communication between neurons. But there's a catch: Too much copper doesn't add extra benefits — it can actually do more harm than good. 'Though copper is necessary for proper functioning of the brain, and deficiencies can lead to neurological disorders, excessive copper can be toxic, leading to oxidative stress and neurodegeneration,' the researchers wrote. Advertisement 4 Roughly 35 million adults experience some form of cognitive impairment. LIGHTFIELD STUDIOS – This damage can disrupt brain function and contribute to the development of chronic health problems like Alzheimer's, Parkinson's and Wilson's disease. Upon further analysis, the scientists found that 1.22 milligrams of dietary copper daily is enough to support your brain health and ward off cognitive decline without going overboard. The implications are significant, especially since research shows nearly 10% of U.S. adults aged 65 and older have dementia, with another 22% experiencing mild cognitive impairment. And those numbers are expected to rise in the coming years. Still, the researchers cautioned that additional long-term studies are needed to confirm their findings. 4 Many nuts and seeds contain substantial amounts of copper. New Africa – Want to boost your copper intake? Your body can't make it on its own, so you've got to get it from your diet. Supplements are one option, but the mineral is also packed into a wide range of foods. Advertisement Top sources of copper: Shellfish, like oysters and crap Organ meats, especially beef liver Other ways to get copper: Advertisement Nuts Seeds Shiitake mushrooms Dried fruits Beans Dark chocolate Whole grains Leafy greens like spinach and kale An added bonus: Copper does way more than just support your brain health. It's key for energy production, making red blood cells, absorbing iron, and keeping your immune system in top shape. Copper also helps maintain healthy blood vessels, nerves and bones — plus it's essential for producing collagen and connective tissue.
Yahoo
5 hours ago
- Yahoo
Arthrex NanoScope™ System Receives Pediatric Clearance for Orthopedic, Laparoscopic Procedures
NAPLES, Fla., July 16, 2025 /PRNewswire/ -- Arthrex, a global leader in minimally invasive surgical technology, announced that it has received U.S. Food and Drug Administration (FDA) clearance to use the Arthrex NanoScope™ operative arthroscopy system for pediatric orthopedics and laparoscopy. The NanoScope system is a compact, high-resolution mobile imaging platform featuring the industry's first high-definition, chip-on-tip camera — known as the NanoNeedle Scope — engineered specifically to meet the unique anatomical and procedural needs of pediatric patients. "This innovative and disruptive technology is transforming the way we approach diagnostic and least-invasive surgical treatments, and we are extremely proud to expand its indications to the field of pediatric orthopedics and laparoscopy," said Arthrex President and Founder Reinhold Schmieding. The NanoScope system can be used in common pediatric cases like general knee arthroscopy, meniscal treatments, anterior cruciate ligament (ACL) reconstruction, general shoulder arthroscopy and hernia or diagnostic laparoscopy in the abdomen. The smaller scope is designed to minimize the potential risk of damaging anatomical structures upon entry along with neurovascular structures. "FDA clearance for use of the NanoScope system in pediatric patients is an important, exciting step forward," said J. Lee Pace, MD. "Its smaller size makes it ideal for navigating pediatric joints while still delivering excellent image quality for routine or even more complex cases." Most Nano arthroscopy procedures can be performed outside of a traditional operating room, such as in a physician's office or an ambulatory surgery center, offering a more convenient and flexible option for both diagnosis and treatment. Patients and doctors can also discuss anesthesia options to determine the level that best fits a particular procedure and the patient's comfort level, from local anesthesia — allowing the patient to stay awake during treatment — to twilight anesthesia, or mild sedation. This minimally invasive approach also means a smaller scar,1 less risk of infection2 and the potential for less pain, reducing the need for prescriptive pain medications.3 To learn more about Nano arthroscopy, visit For more information, downloadable multimedia assets and interview requests for subject matter experts, contact Arthrex Media Relations at media@ About Arthrex Arthrex, headquartered in Naples, Florida, is a global medical device company and leader in multispecialty minimally invasive surgical technology innovation, scientific research, manufacturing and medical education. The company has pioneered the field of arthroscopy and sports medicine and develops more than 1,000 new products and related procedures annually to advance minimally invasive orthopedic surgery, trauma, spine, cardiothoracic, orthobiologics and arthroplasty innovation worldwide. Arthrex also specializes in the latest 4K multispecialty surgical visualization and OR integration technology solutions. For more information, visit Physician is a paid consultant of Arthrex, Inc. References Schaver AL, Lash JG, MacAskill ML, et al. Partial meniscectomy using needle arthroscopy associated with significantly less pain and improved patient reported outcomes at two weeks after surgery: a comparison to standard knee arthroscopy. J Orthop. 2023;41:63-66. doi:10.1016/ McMillan S, Chhabra A, Hassebrock JD, Ford E, Amin NH. Risks and complications associated with intra-articular arthroscopy of the knee and shoulder in an office setting. Orthop J Sports Med. 2019;7(9):2325967119869846. doi:10.1177/2325967119869846 Bradsell H, Lencioni A, Shinsako K, Frank RM. In-office diagnostic needle arthroscopy using the NanoScope™ arthroscopy system. Arthrosc Tech. 2022;11(11):e1923-e1927. doi:10.1016/ View original content to download multimedia: SOURCE Arthrex, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
